Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Johnston SR, Semiglazov VF, Manikhas GM, Spaeth D, Romieu G, Dodwell DJ, Wardley AM, Neven P, Bessems A, Park YC, De Porre PM, Perez Ruixo JJ, Howes AJ. Johnston SR, et al. Among authors: perez ruixo jj. Breast Cancer Res Treat. 2008 Jul;110(2):327-35. doi: 10.1007/s10549-007-9726-1. Epub 2007 Sep 13. Breast Cancer Res Treat. 2008. PMID: 17851757 Clinical Trial.
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA. Rao S, et al. Among authors: perez ruixo jj. J Clin Oncol. 2004 Oct 1;22(19):3950-7. doi: 10.1200/JCO.2004.10.037. J Clin Oncol. 2004. PMID: 15459217 Clinical Trial.
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Cohen SJ, et al. Among authors: perez ruixo jj. J Clin Oncol. 2003 Apr 1;21(7):1301-6. doi: 10.1200/JCO.2003.08.040. J Clin Oncol. 2003. PMID: 12663718 Clinical Trial.
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H, Venkatasubramanian R, Neyens M, Gopal S, Russu A, Nandy P, Perez-Ruixo JJ, Ackaert O. T'jollyn H, et al. Among authors: perez ruixo jj. Eur J Drug Metab Pharmacokinet. 2024 May 20. doi: 10.1007/s13318-024-00899-z. Online ahead of print. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38769284
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
T'jollyn H, Russu A, Venkatasubramanian R, Gopal S, Nandy P, Neyens M, Faelens R, Samtani MN, Ackaert O, Perez-Ruixo JJ. T'jollyn H, et al. Among authors: perez ruixo jj. Eur J Drug Metab Pharmacokinet. 2024 May 15. doi: 10.1007/s13318-024-00900-9. Online ahead of print. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38750386
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
Dari A, Jacqmin P, Iwaki Y, Neyens M, Le Gars M, Sadoff J, Hardt K, Ruiz-Guiñazú J, Pérez-Ruixo JJ. Dari A, et al. Among authors: perez ruixo jj. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1485-1498. doi: 10.1002/psp4.13025. Epub 2023 Sep 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37715342 Free PMC article.
127 results